Drug Trial Radar · NCT04937166
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Last checked: Nov 19, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
25
Actual
Start
Jan 13, 2022
Primary completion
Apr 23, 2025
Study completion Oct 24, 2025
Sponsor
- Lead sponsor
- Kahr MedicalIndustry
- Sponsor type
- Industry
- First posted
- Jun 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be divided into two parts, Parts A and B and will enroll patients with relapsed/refractory AML or MDS/chronic myelomonocytic leukemia (CMML) patients who have failed up to 2 prior therapeutic regimens. Part A is a dose escalation study to explore the safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) profile of DSP107 when administered in combination with azacitidine (AZA). Part B is a dose escalation study to explore the safety, efficacy, PK and PD profile of DSP107 when administered in combination with AZA and venetoclax (VEN).
Conditions
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia
Interventions
DSP107Biological
DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
AzacitidineDrug
Azacitidine is an analog of the pyrimidine nucleoside cytidine.
VenetoclaxDrug
Venetoclax is a B-cell lymphoma (BCL)-2 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (AEs)Time frame: Duration of the study, estimated to be 12 months
- Dose Limiting Toxicities (DLT)Time frame: At the end of Treatment Cycle 2 (within 2 months of treatment initiation)
- Response Rate (RR) including Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (CRi)Time frame: Within 6 months of treatment initiation
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California
The University of Texas MD Anderson Cancer Center, Department of Leukemia
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.